Paliperidone ER for Borderline Personality Disorder
Author Information
Author(s): Silvio Bellino, Paola Bozzatello, Camilla Rinaldi, Filippo Bogetto
Primary Institution: University of Turin
Hypothesis
The study aims to evaluate the efficacy and safety of paliperidone ER in patients with borderline personality disorder.
Conclusion
Paliperidone ER was effective and well tolerated in reducing the severity of global symptomatology and specific BPD symptoms.
Supporting Evidence
- Paliperidone ER showed significant improvements in various scales measuring BPD symptoms.
- Only one severe side effect (hyperprolactinemia) led to treatment discontinuation.
- Adverse effects were generally mild to moderate.
Takeaway
This study tested a new medicine called paliperidone ER to help people with a condition called borderline personality disorder, and it seemed to work well.
Methodology
18 outpatients with BPD were treated for 12 weeks with paliperidone ER and assessed using various scales.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
The sample included 5 males and 13 females, with a mean age of 24.3 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website